- Challenges in patient recruitment for the Phase II clinical trial of FP-045 due to the rarity of Fanconi anemia.
- Rising raw material costs.
- Increased severity of extreme weather events.
Foresee Pharmaceuticals Co., Ltd.
Greenhouse gas emissions & sustainability report data
In its 2023 reporting, Foresee Pharmaceuticals Co., Ltd. disclosed greenhouse gas emissions of 231.817 tCO2e/year. By scope: Scope 1: 1.886 tCO2e/year; Scope 2: 229.931 tCO2e/year. Figures are as stated in the company's own report and may use different boundaries, units or methods (for example market-based vs location-based Scope 2), so compare with care.
GHG Emissions
231.817 tCO2e/year
2023
Waste
1.92 tons/year (liquid); 0.43 tons/year (solid)
2023
📊 Emissions by Scope (2023)
| Scope | What it covers | Reported value |
|---|---|---|
| Scope 1 | Direct emissions from sources the company owns or controls (fuel combustion, company vehicles, process and fugitive emissions). | 1.886 tCO2e/year |
| Scope 2 | Indirect emissions from purchased electricity, steam, heat and cooling. | 229.931 tCO2e/year |
New to scopes? Read Scope 1, 2 and 3 emissions explained and market-based vs location-based Scope 2.
✅ Reported Environmental Achievements
- Implemented energy-efficient LED lighting and improved air conditioning to reduce electricity consumption.
- Reduced per capita emissions by 10% by 2028 compared to 2023.
🎯 Climate & Sustainability Targets
🔜 Short-term
- Reduce per capita emissions by 10% by 2028.
- Complete greenhouse gas inventory and verification by 2028.
- Complete evaluation of suppliers on sustainability aspects by 2026.
📅 Medium-term
- Implement the “Waste Management Procedure Manual”.
- Use ISO 14001 standards as environmental assessment criteria.
🌱 ESG Focus Areas
Corporate GovernanceEnvironmental SustainabilitySocial Responsibility